Favorable reimbursement policies and better healthcare facilities are key factors contributing towards the growth in demand for blood collection tubes for liquid biopsy.

DUBLIN, IRELAND / ACCESSWIRE / February 25, 2020 / The global blood collection tubes for liquid biopsy market is set to rise at a healthy CAGR of 6% between 2019 and 2029, according to the projections of a new study by Fact.MR. Leading manufacturers of blood collection tubes for liquid biopsy are investing efforts in direct sale distribution channels and more effective promotional strategies.

"The healthcare industry is consistently witnessing an increase in the number of biopsy procedures every year, due to the high prevalence of cancer. This, in turn, has led to the growth of the blood collection tubes for liquid biopsy market, which has aided in early diagnosis of cancer," says the Fact.MR report.

Request PDF Sample of 170 pages report on the blood collection tubes for liquid biopsy market-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4495

Blood Collection Tubes for Liquid Biopsy Market Study: Key Findings

Plastic versions of blood collection tubes for liquid biopsy is projected to gain consumer preference over glass alternatives.
The market is at a nascent stage, and the scope for application remains largely limited to the global research industry.
Developed regional markets continue to flourish on the back of high product accessibility.
Sophistication of the medical infrastructure and increasing affordability of healthcare product supports market growth in East and South Asian countries.

Blood Collection Tubes for Liquid Biopsy Market: Key Driving Factors

Healthcare centers are displaying a substantial increase in the adoption of blood collection tubes for liquid biopsy to meet research needs.
Rising prevalence of cancers is a major factor driving the growth of the blood collection tubes for biopsy market.
The rising demand for single needle penetration practices for multiple tests will promote the use of blood collection tubes.

Explore 148 figures, 52 tables in the study. Request TOC of the report at-

https://www.factmr.com/report/4495/blood-collection-tubes-for-liquid-biopsy-market

Key Blood Collection Tubes for Liquid Biopsy Market: Key Restraints

Ineffective treatment methods and the resultant false negatives and positives lead to the use of inappropriate treatments, hampering market growth.

Competition Landscape

The global blood collection tubes for liquid biopsy market is moderately fragmented. Industry leaders are focusing their efforts on conventional blood collection tubes for liquid biopsy offerings. Companies are also focusing on improving their customer reach through direct sales operations via multiple distribution channels. The report provides a detailed analysis of the profiles and strategic developments of key players in the global blood collection tubes for liquid biopsy market, which include but are not limited to, La Roche Ltd., Biomatrica, Qiagen, Biocept Inc., Streck Inc., and Norgen Biotek.

About the Report

This 170-page study provides in-depth forecast data on the blood collection tubes for liquid biopsy market. The key categories covered by the report include product material (plastic and glass), application (IVD and Research Use), end user (healthcare centers, research and development centers, and diagnostic centers) and 25+ countries in key regions (North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa).

Explore Fact.MR's Detailed Coverage of the Healthcare Landscape

Breast Localization Needles Market-The report on breast localization needles covers opportunities for the manufacturers of breast localization needles and analyzes the value chain analysis in detail.

Tracheostomy Equipment Package Market– The report discusses the revenue generated from sales of tracheostomy equipment packages across all key regional economies.

Genitourinary Cancers Treatment Market-The genitourinary cancers treatment market has been assessed in the report on the basis of sales and pricing figures by treatment types.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over thousand reports and 1 million+ data points, the team has scrutinized the Healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai, United Arab Emirates
MARKET ACCESS DMCC Initiative
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog – https://blog.factmr.com/
PR- https://www.factmr.com/media-release/1275/global-blood-collection-tubes-for-liquid-biopsy-market

SOURCE: FactMR

ReleaseID: 577759

NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against 500.com Limited ("500.com" or the "Company") (NYSE:WBAI) and certain of its officers, on behalf of shareholders who purchased 500.com securities between April 27, 2018 and December 31, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:www.bgandg.com/wbai.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) 500.com executives and consultants engaged in a bribery scheme with Japanese officials in an effort to gain favor in a bid to run an upcoming Japanese casino resort; (2) consequently, 500.com was in violation of Japanese anti-bribery laws and its Code of Ethics; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/wbai or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in 500.com you have until March 16, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 576617

Thanks to the Recent Hire, Power Generation Service Can Now Offer Full Service to All of Their Valued Customers

ALBUQUERQUE, NM / ACCESSWIRE / February 25, 2020 / The founder of Power Generation Service, LLC, is pleased to announce the hire of an in-house electrician.

To learn more about Power Generation Service and the services that they offer, please visit https://powergenerationservice.com/about/.

As Jeanette Jennings, the manager of Power Generation Service in Albuquerque noted, while the company has always wanted to provide their customers with a complete package and install the generators that they sell, they have traditionally had to rely on electrician subcontractors.

"We recently made a decision to hire an in-house electrician, which opens up a huge door for us in regards to being able to accommodate the customers' needs under one roof," Jennings said, adding that she and the team from Power Generation Service in New Mexico are proud to be able to provide full electrical service from start to finish.

"We feel like it should be a division of what we do and not just limit ourselves to the installation of the generator, but to be able to provide the customer with full electrical service, even though it may not include a generator installation."

The fact that Power Generation Service has hired an in-house electrician in an effort to better serve their customers will not surprise the many people throughout New Mexico and parts of Arizona that have used the company over the years. Since they first opened for business, Power Generation Service has earned a well-deserved reputation for their outstanding customer service.

"Service and repair are our strongest attributes. And we are working toward providing every aspect of what Power Generation Service can provide to the community, or to the businesses in Albuquerque and New Mexico," Jennings said.

"We are really excited that having an in-house electrician is going to really provide the customer service that we've been looking for. And I think it's also what the customers are looking for."

About Power Generation Service, LLC

Power Generation Service, LLC provides engine and generator service and repair for all major brands. They provide solutions for construction companies, rental yards, homeowners, and many other businesses. From commercial generators to portable power generators, industrial generators and residential generators, Power Generation Service technicians are experts at servicing, diagnosing, and maintaining the most advanced power systems available on the market. Their field service technicians travel the state of New Mexico and parts of Arizona with over 125 years combined experience. For more information, please visit https://powergenerationservice.com/.

Power Generation Service, LLC
5001 Edith Blvd NE
Albuquerque, NM 87107

Contact:

Tad Jennings
Tad@PowerGenerationService.com
(505) 323-2032

SOURCE: Power Generation Service, LLC

ReleaseID: 577747

NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Anadarko Petroleum Corporation ("Anadarko" or the Company") (NYSE:APC), now a wholly-owned subsidiary of Occidental Petroleum Corporation (NYSE: OXY), and certain of its officers, on behalf of shareholders who purchased Anadarko securities between February 20, 2015 and May 2, 2017, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/apc.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the value of the Shenandoah assets and the success of the Shenandoah appraisal wells were overstated; (2) the Company lacked effective internal control over financial reporting; (3) as a result of the foregoing, Defendants' statements about the Company's Shenandoah assets lacked a reasonable basis; and (4) accordingly, the Company's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/apc or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Anadarko you have until April 20, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC
 

ReleaseID: 577410

NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against HP Inc. ("HP" or the Company") (NYSE:HPQ) and certain of its officers, on behalf of shareholders who purchased HP securities between February 23, 2017 to October 3, 2019 inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/hpq.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that material adverse information. Specifically, the complaint alleges that: (1) HP falsely highlighted that the four-box model was an accurate, reliable tool to determine demand and revenue in its Supplies business, and reassured investors that, based on the four-box model, HP had a "clear line of sight to supply stabilization"; (2) defendants repeatedly made false and misleading statements to investors about the reliability of its four-box model and the revenue growth of the Supplies business, touting their "continued confidence in the predictive value of the four box model" and stating that its "Supplies revenue is in line with the expectations that we set and that our 4-box model continues to drive predictability"; and (3) and as a result, HP common stock traded at artificially inflated prices during the Class Period.

If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/hpq, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in HP, you have until April 20, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 577409

Sold Under the Brand Name "Four Robins, Ltd.," Pieces Include Special Gifts for First Communion, Confirmation and Other Christian Milestones

PITTSBURGH, PA / ACCESSWIRE / February 25, 2020 / For the husband and wife artistic team of Greg and Nicole Horgan, their Catholic faith is a source of both guidance in life and creative inspiration. Residing in Saxonburg, PA, just outside of Pittsburgh – a town founded and designed by F. Carl Roebling, who engineered and built the Brooklyn Bridge – the Horgans have built a successful and unique business making leather art that celebrates the region's Catholic immigrant heritage as well as Catholicism itself. Sold under the brand name Four Robins, Ltd., their work incorporates Catholic imagery and Gospel verses into numerous gift items such as leather paper trays, leather valet trays and leather Christmas ornaments. Available for purchase through their website, Amazon and other online retailers, their most popular items commemorate Christian milestones such as Baptism, First Communion and Confirmation.

The Horgans founded their company in 2010. Since then they've produced thousands of items of giftware, sophisticated office products and home accents using natural, vegetable-tanned leather which is hand-formed and results in a rigid, durable final form. All items are handmade in the USA. Toyota Motor Company and other multinationals have used Four Robins products for corporate gifts. Their work has been featured on HGTV Design Blog, ABC-TV, the Cleveland Plain Dealer and the Chicago Tribune, as well as exhibited at arts events such as the American Craft Council.

Greg & Nicole's most recent large-scale piece is a sculpture titled "San Pedro," named both for St. Peter, the apostle of Christ, who witnessed Divinity firsthand, as well as the psychoactive Andean San Pedro Cactus, Echinopsis Pachanoi. Created over six months using 48 square feet of leather, the piece is shaped like a cluster of San Pedro cacti, colorfully painted with mystical and religious imagery, much of it inspired by St. Peters Basilica, Ukrainian Easter Eggs and shamanic geometry. Around the base of the cacti are 1,500 keys, symbolic of the keys to Heaven that St. Peter is said to hold. A 12-minute video on the making of the piece can be viewed on the Four Robins website.

"We chose the San Pedro Cactus because it reflects the trans-national history of our faith, and the metaphorical ways Catholic missionaries communicated historically in environments where there was not a common language," explains Greg Horgan. "Further, we wanted our artwork, aside from our business, to be a gesture of solidarity between Catholics around the world, who have not only shared history, but shared metaphor. This powerful message has already caught the attention of reporters in Poland and Mexico who have written about us."

In addition to their line of Christian gifts, Four Robins, Ltd., also makes recovery gifts, to provide daily inspiration to anyone working to overcome addiction. They also produce leather anniversary gifts (the third year of marriage is traditionally celebrated with a gift made of leather).

For more information and to view the Horgans' Catholic gifts and other items, visit www.FourRobins.com.

CONTACT:

Greg Horgan
+1-412-916-7000
greghorgan150@gmail.com

SOURCE: Four Robins Ltd.

ReleaseID: 577760

NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against JELD-WEN Holding, Inc.

("JELD-WEN" or the Company") (NYSE:JELD) and certain of its officers, on behalf of shareholders who purchased JELD-WEN securities between January 26, 2017 and October 15, 2018, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/jeld.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jeld-Wen products, including doors, compete against other manufacturers on price, and described the market in which the Company sells its doors as "highly competitive"; and (2) Jeld-Wen's strong margins and anticipated margin growth were attributed to legitimate business factors, such as "making strategic pricing decisions based on an analysis of customer and product-level profitability" and increasing its emphasis on "pricing optimization"; (3) these and similar statements made by defendants during the Class Period were false and misleading because defendants knew that Jeld-Wen was engaged in a price-fixing conspiracy with another door manufacturer to artificially increase or maintain prices of interior molded doors; and (4) consequently, Jeld-Wen common stock traded at artificially inflated prices throughout the Class Period.

If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/jeld, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in JELD-WEN, you have until April 20, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 577408

NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (NASDAQ:DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research ("IIBR"), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats.

IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).

The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform known to shorten the development cycle, lower the manufacturing cost and improve the performance of vaccines and mAbs.

"Our collaboration with the IIBR is aimed at finding additional solutions to combat the COVID-19 coronavirus outbreak that threathens the lives of people in China and globally," commented Mark A. Emalfarb, Founder and CEO of Dyadic. "There is a global need to apply new platforms and technologies that will facilitate a fast, coordinated and practical response to new infectious diseases during pandemic and epidemic outbreaks or a bioterrorist attack and we believe that Dyadic's C1 technology is well-positioned to contribute to this global effort."

"Certain data and results generated from this collaboration are expected to futher validate the versatility and safety of our C1 gene expression platform," said Dr. Ronen Tchelet, Dyadic's Chief Scientific Officer.

"The Israel Institute for Biologcal Research was assigned by the Israeli Prime minister, Mr. Benjamin Netanyahu, to act as quickly as possible to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19," said Prof. Shmuel C. Shapira, Director General of IIBR. Prof Shapira continued, "More than 50 experienced Ph.D. IIBR's scientists are working tirelessly to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19. This is a world-leading group in aspect of knowledge, experience and infrastructure. The Israel Institute for biological research was assigned to the task based on its proven professional scientific capabilities and previous successes in the field."

About Israel Institute for Biological Research

The Israel Institute for Biological Research (IIBR) is a national center for research and development that specializes in the fields of biology, chemistry and the environmental sciences, and aims to enhance Israel's strengths and fortitude. IIBR recruits leading Israeli scientists and benefits from cutting edge technologies and infrastructure built to serve the topmost research and strict safety standards. IIBR capabilities, scientific achievements and decades of advanced R&D lead to national and international reputation and prestigious collaborations.

https://iibr.gov.il/Pages/home.aspx

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.

Please visit Dyadic's website at http://www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company's most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website and at http://www.dyadic.com.

Contact:

Israel Institute of Biologic Research
Sharron Harnoy
Phone: 972 8 9381540
Email: mailto:sharronh@iibr.gov.il

Dyadic International, Inc.
Mark Emalfarb, CEO
Phone: +1 (561) 743-8333
Email: memalfarb@dyadic.com

SOURCE: Dyadic International, Inc.

ReleaseID: 577763

Newswire's team of experts help major financial service companies with their media outreach and marketing campaigns.

NEW YORK, NY / ACCESSWIRE / February 25, 2020 / With other priority tasks at hand, major financial services companies have decided to sign on the Earned Media Advantage Guided Tour, having Newswire's expert Earned Media Advantage Strategist aid their team with media and marketing communications needs. Before signing on with the Guided Tour, financial service companies had been creating ineffective media outreach campaigns that did not resonate with the right contacts. Having a seasoned strategist involved in the process has given these companies the opportunity to step-up their marketing campaigns, which have had a significant impact on media relations efforts.

Financial Services Companies Trust the Earned Media Advantage Guided Tour for Their Media and Marketing Communications Needs

"We have seen a great increase in interest from the media regarding our financial service companies who have signed on with the Guided Tour," said Charlie Terenzio, Director of Earned Media Strategy​. "Our strategists know how to effectively reach the right journalists, bloggers, producers, etc. and connect them to our clients."

While on the Guided Tour, financial service companies have seen a twenty-five percent increase in email opens from the media, significantly higher than the stagnant two percent open rate they had previously received. Newswire strategists understand sending out the right message at the right time is critical to all media outreach efforts. Hence why creating a ‘customerized' Earned Media Advantage Plan that is available on-demand is critical to each campaign.

Terenzio said, "Through our best class platform, we are able to track email sends, open rates, and click-through rates and report back to each financial service company. Since signing on with the Guided Tour, there has been a noticeable uptick in their outreach results."

The Guided Tour helps businesses address the challenges related to their media and marketing efforts by providing the ability to leverage a dedicated Earned Media Advantage Strategist at Newswire to develop and implement a ‘customerized' plan to meet their business objectives. Through the Guided Tour program, customers can experience Newswire's high-tech, high-touch service and industry-leading support throughout the journey for the Earned Media Advantage: greater brand awareness, increase website traffic, greater return on media and marketing communications spend, and increased sales.

By providing a fully integrated media and marketing communications strategy to deliver results, customers can have the right plan that is implemented via the right message and sent out at the right time to the right people. Rated #1 in customer satisfaction, Newswire continues to excel in industry with its best-in-class platform and customer service by providing businesses a cost-effective media and marketing solution to support their sales and marketing efforts.

Discover How the Earned Media Advantage is Transforming Business today and learn how you can generate greater value and ROI across all of your PR campaigns.

About Newswire​

Newswire delivers press release and multimedia distribution software and services (SaaS) that empower the Earned Media Advantage: greater brand awareness, increased traffic, greater return on media and marketing communications spend and the competitive edge. With over a decade of experience, Newswire continues to provide its customers with the ability to deliver the right message to the right audience at the right time through the right medium.​

To learn about and experience Newswire, visit http://www.newswire.com.

Contact Information

Charlie Terenzio
Director of Earned Media Strategy
​Newswire
​Office: 813-480-3766
Email: charlie@newswire.com

SOURCE: Newswire

ReleaseID: 577762

High demand from ruminant animal farmers and advances in semen collection procedures collectively drive demand for animal artificial inseminations processes.

DUBAI, UAE / ACCESSWIRE / February 25, 2020 / In view of growing demand for genetically modified breeds of livestock, the global animal artificial insemination market is projected to grow at a healthy 5.4% CAGR through the forecast period (2019 – 2029). Between 2019 and 2029, the animal artificial inseminations market revenues are set for 1.7X expansion, as suggested by a new Future Market Insights (FMI) study.

"Growing adoption of advanced semen sexing technologies for animal breeding, aquaculture, and dairy farming is projected to propel growth of animal artificial insemination market," says the FMI analyst.

Download PDF sample of the 291-page report on the animal artificial inseminations market https://www.futuremarketinsights.com/reports/sample/rep-gb-10831

Key Takeaways of the Animal Artificial Inseminations Study

Reagent media is remains a highly preferred product owing to growing importance of semen culture.
Semen collection procedures account for around three quarters of the overall market revenue with advances in relevant technology.
Animal artificial insemination will find significant application in ruminants, accounting for a major market share.
North America and East Asia are key regional markets, with government support for indigenous animal breeds and animal food production.

Animal Artificial Inseminations Market – Top Growth Drivers

Rising investments in artificial insemination procedures for ruminants and canine are key growth drivers.
Frequent new launches and introduction of new insemination processes push developments in the industry.
Improving pet insurance scenario and increased presence of third-party players are boosting the market revenue.
Adoption of animal artificial insemination procedures is heightening, with the rise in private animal health care centers.
Awareness programs about zoonotic diseases contribute to overall demand.

Animal Artificial Inseminations Market – Key Restraints

The risk of contamination or transmission of diseases through semen restrict the growth of animal artificial insemination market.
Intense selection of parent animals for breeding are narrowing genetic variations, which continues to limit market growth.

Explore 63 tables and 116 figures in the study. Request ToC of the report at

https://www.futuremarketinsights.com/askus/rep-gb-10831

Competitive Landscape

Some of the prominent players that are covered by the study include, but are not limited to, ABS Global Inc., Accelerated Genetics, Boehringer Ingelheim, Merck & Co. Inc., Zoetis Inc., Elanco Animal Health, All Star Genetics, World Wide Sires, Alta Genetics, ST Genetics, Semex and more. Leading players in the field of animal insemination are acquiring smaller competitors in the industry to expand market share and build a product portfolio. Further, key players are pushing for better distribution presence in individual regions to boost the scope of setting up manufacturing settings.

More about the Report

The 291-page study offers an in-depth market forecast and analysis on the animal artificial inseminations market. The major categories encompassed by the report include product type (insemination equipment, artificial insemination syringes, insemination sheaths, artificial insemination applicators, artificial insemination straws, thawers, accessories, artificial insemination kits, reagent media, and others), procedure (semen collection procedures, and insemination procedures), animal type (canine, feline, swine, bovine, equine, and ruminant), end user (animal hospitals, animal clinics, animal breeding centers, and others) across seven regions (South Asia, East Asia, Latin America, Europe, North America, Middle East & Africa, and Oceania).

Explore Extensive Coverage of FMI's Industrial Automation & Equipment Landscape

Arthroscopy Procedures and Products Market– Get FMI's latest growth predictions on the global arthroscopy procedures and products market with exclusive assessment of market dynamics, segmentation, historic, current, and future growth prospects of the global arthroscopy procedures and products market.

Hips and Knees Reconstructive Market– FMI's comprehensive documentation of the global hips and knees reconstructive market covers segmental analysis, market performance, key trends, and prominent players with their respective market shares, developmental strategies, and business models.

Generic Oncology Drugs Market– Obtain accurate quantitative and qualitative insights on the global generic oncology drugs market encompassing revenue statistics, successful market strategies, competitive landscape, key regions, and growth drivers for 2018-2028 projection period.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in U.S. and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.

CONTACT:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Market Report: https://www.futuremarketinsights.com/reports/animal-artificial-insemination-market
Press Release Source: https://www.futuremarketinsights.com/press-release/animal-artificial-insemination-market

SOURCE: Future Market Insights

ReleaseID: 577750